S&P 500 7,609.78 +0.13% NASDAQ 27,093.90 +0.03% DOW 51,307.79 +0.45% R2K 2,931.96 +0.90% VIX 16.06 +1.84%
Next Bullish Trade
DXCM DexCom, Inc. NMS
$73.45 -1.42 (-1.90%)
Blow-off · +2.03σ Hot zone Grade B
+ Compare Set alert Open in Sniper

Price chart

Overlay: Click earnings ▲ markers for day-move details

Loading 1Y daily…

Financial overlay · last 12 quarters

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $1.2B $0.2B $0.3B $0.4B 16.7% 21.4%
2025-12-31 $1.3B $0.3B $0.3B $0.2B 21.2% 25.6%
2025-09-30 $1.2B $0.3B $0.2B $0.6B 23.5% 20.1%
2025-06-30 $1.2B $0.2B $0.2B $0.2B 15.5% 18.4%
2025-03-31 $1.0B $0.1B $0.1B $0.1B 10.2% 12.9%

Earnings replay · last 20 reports

DateEPS actual EPS estSurprise
2026-04-30 0.56 0.47 +19.0%
2026-02-12 0.68 0.65 +4.5%
2025-10-30 0.61 0.57 +7.5%
2025-07-30 0.48 0.44 +8.2%
2025-05-01 0.32 0.33 -2.6%
2025-02-13 0.45 0.50 -9.9%
2024-10-24 0.45 0.43 +3.5%
2024-07-25 0.43 0.39 +11.4%
2024-04-25 0.32 0.27 +18.6%
2024-02-08 0.50 0.43 +16.0%
2023-10-26 0.50 0.33 +50.0%
2023-07-27 0.34 0.23 +50.6%
2023-04-27 0.17 0.15 +17.1%
2023-02-09 0.34 0.28 +23.1%
2022-10-27 0.28 0.24 +15.8%
2022-07-28 0.17 0.19 -10.2%
2022-04-28 0.08 0.13 -38.8%
2022-02-10 0.17 0.21 -19.9%
2021-10-28 0.22 0.16 +37.8%
2021-07-29 0.19 0.11 +71.0%

Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).

Peer comparison · Healthcare

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
DXCM ★ $28B 31.5 23.9 5.9 21.1 9.6 61.5% 15.0% 92.2% 3.73%
LLY $949B 37.7 23.9 13.1 27.3 30.5 82.8% 55.5% 169.9% 0.96%
UNH $343B 28.5 18.1 0.8 18.5 3.5 18.8% 2.0% 0.7% 5.15%
JNJ $537B 25.8 17.5 5.6 16.6 6.6 68.0% 9.9% -52.9% 2.33%
MRK $286B 32.6 12.1 4.3 11.2 6.2 76.7% 4.9% — 4.92%
ABBV $381B 105.1 13.3 6.1 14.8 -57.2 72.0% 12.4% -46.2% 5.47%
PFE $146B 19.5 9.0 2.3 7.8 1.6 74.8% 5.4% -10.1% 8.50%
TMO $179B 26.5 17.7 4.0 19.4 3.4 40.9% 6.2% 11.3% 3.08%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Top institutional holders

Top-10 concentration: 43.39%

HolderShares% out
Blackrock Inc. 38,964,371 10.10%
Vanguard Capital Management LLC 25,020,961 6.48%
Vanguard Portfolio Management LLC 19,219,953 4.98%
State Street Corporation 17,934,847 4.65%
BAILLIE GIFFORD & CO 15,599,525 4.04%
Alliancebernstein L.P. 12,923,644 3.35%
Geode Capital Management, LLC 12,346,638 3.20%
UBS AM, a distinct business unit of 9,746,174 2.53%
Wellington Management Group, LLP 9,326,240 2.42%
Amundi 6,332,561 1.64%

Insider activity · 90d

No insider trades for DXCM in last 90d.

Analyst estimates

yfinance
Low
$65.0
Mean
$82.79167
High
$112.0
Analysts
24

Consensus: strong_buy (mean 1.33333). Distribution requires FINNHUB_API_KEY.

SEC filings

FormFiled DescriptionAction
4 2026-06-01 FORM 4 view ·
4 2026-06-01 FORM 4 view ·
4 2026-06-01 FORM 4 view ·
4 2026-06-01 FORM 4 view ·
4 2026-06-01 FORM 4 view ·
4 2026-06-01 FORM 4 view ·
4 2026-06-01 FORM 4 view ·
4 2026-06-01 FORM 4 view ·
4 2026-06-01 FORM 4 view ·
4 2026-06-01 FORM 4 view ·
8-K 2026-05-28 8-K view ·
4 2026-05-27 FORM 4 view ·
4 2026-05-27 FORM 4 view ·
4 2026-05-27 FORM 4 view ·
4 2026-05-27 FORM 4 view ·
4 2026-05-27 FORM 4 view ·
4 2026-05-26 FORM 4 view ·
4 2026-05-19 FORM 4 view ·
8-K 2026-05-15 8-K view ·
4 2026-05-14 FORM 4 view ·
4 2026-05-11 FORM 4 view ·
4 2026-05-11 FORM 4 view ·
4 2026-05-11 FORM 4 view ·
4 2026-05-11 FORM 4 view ·
10-Q 2026-04-30 10-Q view ·
8-K 2026-04-30 8-K view ·
4 2026-04-16 FORM 4 view ·
DEF 14A 2026-04-15 DEF 14A view ·
4 2026-03-18 FORM 4 view ·
4 2026-03-10 FORM 4 view ·
4 2026-03-10 FORM 4 view ·
4 2026-03-10 FORM 4 view ·
4 2026-03-10 FORM 4 view ·
4 2026-03-10 FORM 4 view ·
4 2026-03-10 FORM 4 view ·
8-K 2026-03-02 8-K view ·
4 2026-02-26 FORM 4 view ·
8-K 2026-02-26 8-K view ·
4 2026-02-17 FORM 4 view ·
10-K 2026-02-12 10-K view ·
8-K 2026-02-12 8-K view ·
4 2026-02-02 FORM 4 view ·
4 2026-02-02 FORM 4 view ·
4 2026-02-02 FORM 4 view ·
4 2026-02-02 FORM 4 view ·
4 2026-02-02 FORM 4 view ·
8-K 2026-01-12 8-K view ·
8-K 2025-12-22 8-K view ·
4 2025-11-17 FORM 4 view ·
4 2025-11-12 FORM 4 view ·
4 2025-11-10 FORM 4 view ·
4 2025-11-10 FORM 4 view ·
10-Q 2025-10-30 10-Q view ·
8-K 2025-10-30 8-K view ·
4 2025-10-28 FORM 4 view ·
8-K 2025-10-27 8-K view ·
8-K 2025-09-16 8-K view ·
4 2025-09-09 FORM 4 view ·
4 2025-09-08 FORM 4 view ·
4 2025-09-04 FORM 4 view ·

About

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.